Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $0.69, with 4.04 million shares of worth about $2.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.07% during that period and on December 04, 2024 the price saw a loss of about -3.89%. Currently the company’s common shares owned by public are about 361.49M shares, out of which, 168.63M shares are available for trading.
Stock saw a price change of -16.46% in past 5 days and over the past one month there was a price change of -43.14%. Year-to-date (YTD), LXRX shares are showing a performance of -55.22% which decreased to -40.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.70 but also hit the highest price of $3.73 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 3.28 million. The stock is currently trading -28.00% below its 20-day simple moving average (SMA20), while that difference is down -51.17% for SMA50 and it goes to -61.58% lower than SMA200.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 361.49M outstanding shares and institutions hold larger chunk of about 29.64% of that.
The stock has a current market capitalization of $247.70M and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 7.43 while making debt-to-equity ratio of 0.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 7.74% while standing at 10.23% over the month.
Stock’s fiscal year EPS is expected to rise by 14.05% while it is estimated to increase by 32.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 17, 2024 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Leerink Partners stated Lexicon Pharmaceuticals Inc (LXRX) stock as an Outperform in their note to investors on April 30, 2024, suggesting a price target of $5 for the stock. On March 07, 2023, Jefferies Initiated their recommendations, while on August 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $10. Stock get a Neutral rating from JP Morgan on January 29, 2021.
